CervoMed is developing neflamapimod, a selective small molecule inhibitor of p38 alpha kinase, to reverse synaptic dysfunction in early-stage neurodegenerative diseases such as Alzheimer's and dementia with Lewy bodies. This approach targets the underlying mechanisms of cognitive decline, aiming to improve memory and cognitive function before significant nerve cell damage occurs.
Funding
$149.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like Alzheimer's and dementia with Lewy bodies cause synaptic dysfunction, leading to impaired memory, focus, and cognitive abilities. Current treatments often address symptoms but fail to target the underlying mechanisms of cognitive decline in the early stages of these diseases. This results in limited effectiveness in reversing or slowing disease progression before significant nerve cell damage occurs.
Solution
CervoMed is developing neflamapimod, an oral, selective small molecule inhibitor of p38 alpha kinase, designed to reverse synaptic dysfunction in early-stage neurodegenerative diseases. By inhibiting p38 alpha, neflamapimod aims to address the reversible aspect of the neurodegenerative process, potentially improving cognitive function and memory. The therapeutic approach focuses on intervening early in the disease process to prevent further cognitive decline. Clinical studies suggest that neflamapimod can reverse the synaptic dysfunction that underlies the development of symptoms and disease progression in the early stages of neurological disorders.
Target Audience
The primary target audience includes individuals in the early stages of neurodegenerative diseases such as Alzheimer's and dementia with Lewy bodies, as well as those seeking to improve cognitive function following a stroke.
Features
- Oral administration for convenient dosing
- Selective inhibition of p38 alpha kinase to target synaptic dysfunction
- Designed to reverse the reversible aspects of neurodegenerative diseases
- Focuses on early intervention to prevent further cognitive decline
- Potential application in Alzheimer's disease, dementia with Lewy bodies, and stroke recovery